IP Library Granted Patent US 11,618,876
Granted Patent B2
US 11,618,876 · App. 15/734,128 · Granted Apr 4, 2023

Method and apparatus for processing tissue samples

Inventors: Stevan Bogdan Jovanovich (Livermore, CA); Kaiwan Chear (Livermore, CA); Bruce Leisz (San Jose, CA); David Eberhart (Santa Clara, CA); John Bashkin (Fremont, CA)
Assignee: S2 GENOMICS, INC.
C12M45/02C12M41/12C12M45/06C12M45/09C12M45/20C12N1/066G01N1/286G01N1/31G01N1/4077G01N2001/4088
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,618,876
App. No.
15/734,128
Granted
Apr 4, 2023
Kind
B2
Abstract

A system, methods, and apparatus are described to collect and prepare single cells, nuclei, subcellular components, and biomolecules from specimens including tissues and in some embodiments use the single cells to form organoids or microtissues. The system can perform enzymatic and/or physical disruption of the tissue to dissociate it into single-cells and then use a hanging droplet method to form organoids or microtissues.

Claims (48)

1. A method comprising:

(a) providing a cartridge

wherein the cartridge comprises:

(1) a preprocessing chamber comprising a grinding surface comprising grinding teeth; and a tissue disrupter comprising a plunger comprising a head comprising a surface comprising grinding teeth and a circumference which provides a gap between the plunger head and a wall of the preprocessing chamber between about 25 microns and 400 microns, wherein the prepossessing chamber comprises a tissue or cell sample; and

(2) a plurality of cartridge ports in a side wall of the preprocessing chamber, wherein the cartridge ports are in fluid communication with the preprocessing chamber;

(b) engaging the cartridge with an instrument

wherein the instrument comprises:

(1) a cartridge interface comprising a plurality of fluid ports engaged with the cartridge ports;

(2) a fluidics subsystem comprising one or more pumps and fluid lines communicating with the fluid ports in the cartridge interface wherein the fluidics subsystem further comprises a source of liquids communicating with the one or more pumps;

(3) an actuator that moves the tissue disruptor along a Z axis of the plunger and rotates the tissue disruptor; and

(b) disrupting the tissue sample by using the actuator to actuate the tissue disrupter to grind the tissue or cell sample between the grinding teeth and the grinding surface to produce a suspension of biological material; and

(c) using the fluidic subsystem to move the suspension of biological material out of the preprocessing chamber.

2. The method of claim 1 , wherein at least one of the fluids comprises one or more enzymes, and disrupting further comprises using the fluidic subsystem to move one or more enzymes for digesting extracellular matrix into the prepossessing chamber.

3. The method of claim 1 , wherein at least one of the fluids comprises one or more detergents, and disrupting further comprises using the fluidic subsystem to move one or more detergents for lysing cell membranes into the preprocessing chamber.

4. The method of claim 1 , wherein disrupting comprises positioning the surface of the head one or more defined distances from a bottom surface of the preprocessing chamber and rotating the head to disrupt tissue in the preprocessing chamber.

5. The method of claim 1 , comprising:

disrupting tissue with the tissue disruptor;

incubating the disrupted tissue in the preprocessing chamber with at least one enzyme that digests extracellular matrix; and

disrupting the incubated tissue with the tissue disruptor.

6. The method of claim 1 , wherein moving the suspension comprises passing the suspension through a strainer or stacked strainers to remove clumps or debris from the suspension.

7. The method of claim 1 , wherein the system further comprises a temperature regulating subsystem; and the method further comprises:

(d) using the temperature regulating subsystem to maintain temperature in the preprocessing chamber.

8. The method of claim 1 , wherein disruption comprises a plurality of disruption cycles, wherein each disruption cycle comprises lowering the plunger and rotating the plunger.

9. The method of claim 1 , wherein the suspension comprises single cells, and moving comprises moving the single cells out of the preprocessing chamber.

10. The method of claim 1 , wherein the suspension comprises isolated nuclei, and moving comprises moving the isolated nuclei out of the preprocessing chamber.

11. The method of claim 1 , wherein disrupting comprises, for isolated nuclei:

(i) using the fluidic subsystem to move one or more solutions into the preprocessing chamber, wherein the solutions comprise one or more of: detergents, surfactants, non-ionic surfactants, Triton X-100, Tween, Brij, CHAPS, Nonidet P40, Igepal, glycosides, HEGA, MEGA, digitonin and DNase; and

using the fluidic subsystem to move the suspension comprising isolated nuclei out of the preprocessing chamber.

12. The method of claim 1 , wherein disrupting comprises, for single cells:

(i) using the fluidic subsystem to move one or more solutions into the preprocessing chamber, wherein the solutions comprise one or more of: collagenases, elastase, trypsin, papain, tyrpLE, hyaluronidase, chymotrypsin, neutral protease, pronase, liberase, clostripain, caseinase, neutral protease (Dispase®), DNAse, protease XIV, an RNase inhibitor, a protease inhibitor, an active site inhibitor, EDTA, EGTA, and sodium citrate; and

using the fluidic subsystem to move the suspension comprising single cells out of the preprocessing chamber.

13. The method of claim 1 , comprising:

incubating the disrupted tissue with at least one enzyme that digests extracellular matrix; and

disrupting the incubated tissue with the tissue disruptor.

14. The method of claim 1 , comprising:

incubating the disrupted tissue with at least one detergent that lyses cell membranes; and

disrupting the incubated tissue with the tissue disruptor.

15. The method of claim 1 , wherein the gap between the head and the wall of the preprocessing chamber is between 200 μm and 500 μm; whereby disrupting produces a single cell suspension.

16. The method of claim 1 , wherein the gap between the head and the wall of the preprocessing chamber is between 50 μm and 250 μm; whereby disrupting produces an isolated nuclei suspension.

17. The method of claim 1 , comprising, after disrupting the tissue, pushing the suspension around and above the head through the side gap between the head and the wall of preprocessing chamber, and moving the suspension from a port positioned above the head.

18. The method of claim 1 , wherein the cartridge is engaged to the instrument through a cartridge port comprising a port cover that creates a seal between the port and the fluid port.

19. The method of claim 1 , wherein the process is executed by a computer comprising scripts.

20. The method of claim 19 , wherein the scripts can be revised, created, or edited by the operator.

21. The method of claim 19 , wherein the computer can be controlled by a user through a user interface.

22. The method of claim 1 , wherein moving the suspension out of the preprocessing chamber comprises moving the suspension into a processing chamber in the cartridge.

23. The method of claim 22 , further capturing single cells or isolated nuclei in the processing chamber with antibodies, and washing to remove debris.

24. The method of claim 1 , comprising regulating temperature in the preprocessing chamber.

25. The method of claim 1 , wherein the suspension is moved out of the preprocessing chamber through a port in a side wall of the preprocessing chamber.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE COVER SHEET. THE CORRESPONDENCE EMAIL IS [email protected] AND THE CORRECT CORRESPONDENT ADDRESS LINE 1 IS STORELLA P.C. PREVIOUSLY RECORDED ON REEL 74251 FRAME 695. ASSIGNOR(S) HEREBY CONFIRMS THE UNDERLYING MERGER ASSIGNMENT. Recorded Apr 13, 2026
From: S2 GENOMICS, INC.
To: S2 GENOMICS, INC.
Reel/Frame 075391/0904 →
MERGER Recorded Apr 1, 2026
From: S2 GENOMICS, INC.
To: S2 GENOMICS, INC.
Reel/Frame 074251/0695 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2021
From: JOVANOVICH, STEVAN BOGDAN; CHEAR, KAIWAN; LEISZ, BRUCE; EBERHART, DAVID; BASHKIN, JOHN
To: S2 GENOMICS, INC.
Reel/Frame 055515/0084 →
Continuity (3)
Provisional Application 62679494 · Jun 1, 2018
Related Publication 20210214673A1 · Jul 15, 2021
Related Publication 20220290092A9 · Sep 15, 2022